Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

Harbin Medical University

Status: Unknown

Conditions: PCSK9

Treatments: Diagnostic Test: Enzyme-linked immunosorbent assay for PCSK9

Study type: Observational

Funder types: Other

Identifiers

NCT05191342

Atrial fibrillation and RA

Details and patient eligibility

About

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.

Full description

Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation.

Enrollment: 75 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Rheumatoid arthritis
2. Rheumatoid arthritis combined with AF

Exclusion criteria

1. (1) History of hypertension, diabetes, cardiovascular disease, severe impairment of liver function, severe renal insufficiency.

(2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.

2. (1) History of hypertension, diabetes, cardiovascular disease (except for AF), severe impairment of liver function, severe renal insufficiency.

(2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.

Trial design

75 participants in 3 patient groups

Rheumatoid arthritis

Description:

Patients with rheumatoid arthritis (n=25).

Treatment:

Diagnostic Test: Enzyme-linked immunosorbent assay for PCSK9

Rheumatoid arthritis complicated atrial fibrillation

Description:

Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).

Treatment:

Diagnostic Test: Enzyme-linked immunosorbent assay for PCSK9

healthy volunteers

Description:

Healthy volunteers (n=25).

Treatment:

Diagnostic Test: Enzyme-linked immunosorbent assay for PCSK9